Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Selenium supplementation in individuals with newly diagnosed Graves’ hyperthyroidism:a double-blind, multi-centre RCT

Title: Selenium supplementation in individuals with newly diagnosed Graves’ hyperthyroidism:a double-blind, multi-centre RCT
Authors: Cramon, Per K.; Winther, Kristian H.; Boesen, Victor B.; Larsen, Camilla B.; Bjorner, Jakob B.; Nordqvist, Selma F.; Forman, Julie L.; Juul, Anne B.; Bach-Mortensen, Pernille; Knudsen, Nils; Nolsøe, Runa L.; Vilsbøll, Tina; Andries, Alin; Gram, Jeppe; Nygaard, Birte; Demircan, Kamil; Chillon, Thilo S.; Schomburg, Lutz; Hegedüs, Laszlo; Bonnema, Steen J.; Feldt-Rasmussen, Ulla; Rasmussen, Åse K.; Watt, Torquil
Source: Cramon, P K, Winther, K H, Boesen, V B, Larsen, C B, Bjorner, J B, Nordqvist, S F, Forman, J L, Juul, A B, Bach-Mortensen, P, Knudsen, N, Nolsøe, R L, Vilsbøll, T, Andries, A, Gram, J, Nygaard, B, Demircan, K, Chillon, T S, Schomburg, L, Hegedüs, L, Bonnema, S J, Feldt-Rasmussen, U, Rasmussen, Å K & Watt, T 2026, 'Selenium supplementation in individuals with newly diagnosed Graves’ hyperthyroidism : a double-blind, multi-centre RCT', European Thyroid Journal, vol. 15, no. 1, ETJ250264. https://doi.org/10.1530/ETJ-25-0264
Publication Year: 2026
Collection: University of Southern Denmark: Research Output / Syddansk Universitet
Subject Terms: Graves’ disease; Graves’ hyperthyroidism; pragmatic trial; quality of life; selenium; ThyPRO
Description: Purpose: We examined the effect of selenium vs placebo on remission rate and quality of life (QoL) in the Graves’ selenium supplementation (GRASS) trial (ID: NCT01611896). Methods: Double-blinded, placebo-controlled, multi-centre trial in individuals with newly diagnosed Graves’ hyperthyroidism randomised to daily supplementation with 200 μg selenium or placebo tablets during 24–30 months, depending on the timing of antithyroid drug (ATD) withdrawal. The primary outcome was the proportion of participants with non-remission, defined as receiving ATD or remaining hyperthyroid (thyroid stimulating hormone
Document Type: article in journal/newspaper
File Description: application/pdf
Language: English
ISSN: 2235-0640; 2235-0802
Relation: info:eu-repo/semantics/altIdentifier/pmid/41384622; info:eu-repo/semantics/altIdentifier/pissn/2235-0640; info:eu-repo/semantics/altIdentifier/eissn/2235-0802
DOI: 10.1530/ETJ-25-0264
Availability: https://portal.findresearcher.sdu.dk/da/publications/0a78472b-e532-4391-be81-faecccaca72f; https://doi.org/10.1530/ETJ-25-0264; https://findresearcher.sdu.dk/ws/files/304917551/etj-ETJ-25-0264.pdf
Rights: info:eu-repo/semantics/openAccess ; http://creativecommons.org/licenses/by/4.0/
Accession Number: edsbas.B5AD0559
Database: BASE